Marpai, Inc. reported Q1 2026 results showing a net revenue of $4.4 million and a net loss of $3.2 million, reflecting investments in cloud migration and operational improvements. The company is finalizing its IT and claims processing migration to a unified cloud platform, expected to reduce costs and improve service from Q2 2026 onward. MarpaiRx, its pharmacy benefit management division, is gaining momentum with new marketing agreements and client wins, supporting revenue growth. Management remains confident in achieving run-rate profitability in the second half of 2026, driven by revenue recovery, cost efficiencies, and a strengthened balance sheet after a debt amendment.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
